Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a study titled ‘Non-interventional Prospective Descriptive Study to Assess the Impact on Patient’s Well-being of Fixed-time Duration (FTD) and Continuous Oral Regimens for Newly Diagnosed and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain.’ The study aims to evaluate the impact of oral treatments on the quality of life and functioning of adult participants with CLL, a prevalent leukemia in the Western world.
The study involves oral treatments for CLL, administered as per the approved local label, to assess their impact on patients’ well-being. These treatments are intended to improve quality of life and prolong survival in CLL patients.
This observational study follows a cohort model with a prospective time perspective. It is designed to be non-interventional, meaning participants will receive treatments during routine clinical practice without additional burdens.
The study began on November 6, 2023, with an anticipated duration of 18 months. The last update was submitted on July 14, 2025, indicating ongoing recruitment and data collection.
For investors, this study highlights AbbVie’s commitment to enhancing CLL treatment, potentially boosting investor confidence and impacting stock performance positively. The study’s progress could influence market dynamics, especially in comparison to competitors in the leukemia treatment space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.